Erratum: Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults (Canadian Journal of Cardiology (2017) 33(5) (557–576) (S0828282X17301101)(10.1016/j.cjca.2017.03.005));Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults

Canadian Journal of Cardiology

Volumn 33, Issue 5, 2017, Pages 557-576

  Leung, Alexander A ^a   Daskalopoulou, Stella S ^b   Dasgupta, Kaberi ^b   McBrien, Kerry ^a   Butalia, Sonia ^c   Zarnke, Kelly B ^d   Nerenberg, Kara ^a   Harris, Kevin C ^e   Nakhla, Meranda ^f   Cloutier, Lyne ^g   Gelfer, Mark ^e   Lamarre Cliche, Maxime ^h   Milot, Alain ⁱ   Bolli, Peter ^j   Tremblay, Guy ^k   McLean, Donna ^l   Tobe, Sheldon W ^m   Ruzicka, Marcel ⁿ   Burns, Kevin D ⁿ   Vallée, Michel ^o   Prasad, G V Ramesh ^m   Gryn, Steven E ^p   Feldman, Ross D ^q   Selby, Peter ^m   Pipe, Andrew ^r   Schiffrin, Ernesto L ^s   McFarlane, Philip A ^t   Oh, Paul ^u   Hegele, Robert A ^p   Khara, Milan ^e   Wilson, Thomas W ^v   Penner, S Brian ^w   Burgess, Ellen ^a   Sivapalan, Praveena ^v   Herman, Robert J ^d   Bacon, Simon L ^x   Rabkin, Simon W ^e   Gilbert, Richard E ^t   Campbell, Tavis S ^a   Grover, Steven ^y   Honos, George ^z   Lindsay, Patrice ^aa   Hill, Michael D ^ab   Coutts, Shelagh B ^ab   Gubitz, Gord ^ac   Campbell, Norman R C ^a   Moe, Gordon W ^t   Howlett, Jonathan G ^d   Boulanger, Jean Martin ^ad   Prebtani, Ally ^j   Kline, Gregory ^a   Leiter, Lawrence A ^ae   Jones, Charlotte ^af   Côté, Anne Marie ^ad   Woo, Vincent ^w   Kaczorowski, Janusz ^ag   Trudeau, Luc ^ah   Tsuyuki, Ross T ^l   Hiremath, Swapnil ⁿ   Drouin, Denis ⁱ   Lavoie, Kim L ^ai   Hamet, Pavel ^z   Grégoire, Jean C ^aj   Lewanczuk, Richard ^l   Dresser, George K ^ak   Sharma, Mukul ^al   Reid, Debra ^am   Lear, Scott A ^an   Moullec, Gregory ^ao   Gupta, Milan ^j   Magee, Laura A ^ap   Logan, Alexander G ^m   Dionne, Janis ^e   Fournier, Anne ^aq   Benoit, Geneviève ^aq   Feber, Janusz ^ar   Poirier, Luc ^k   Padwal, Raj S ^l   Rabi, Doreen M ^d   more..

^a UNIVERSITY OF CALGARY   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f MONTREAL CHILDREN S HOSPITAL   (Canada)

^g UNIVERSITÉ DU QUÉBEC À TROIS RIVIÈRES   (Canada)

^h CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

ⁱ UNIVERSITÉ LAVAL   (Canada)

^j MCMASTER UNIVERSITY   (Canada)

^k LAVAL UNIVERSITY   (Canada)

^l UNIVERSITY OF ALBERTA   (Canada)

^m UNIVERSITY OF TORONTO   (Canada)

ⁿ OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^o MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^p UNIVERSITY OF WESTERN ONTARIO   (Canada)

^q MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^r UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^s MCGILL UNIVERSITY   (Canada)

^t ST MICHAEL'S HOSPITAL   (Canada)

^u UNIVERSITY HEALTH NETWORK   (Canada)

^v UNIVERSITY OF SASKATCHEWAN   (Canada)

^w UNIVERSITY OF MANITOBA   (Canada)

^x Gina Cody School of Engineering and Computer Science   (Canada)

^y MONTREAL GENERAL HOSPITAL   (Canada)

^z UNIVERSITÉ DE MONTRÉAL   (Canada)

^aa UNIVERSITY OF TORONTO   (Canada)

^ab UNIVERSITY OF CALGARY   (Canada)

^ac DALHOUSIE UNIVERSITY   (Canada)

^ad UNIVERSITÉ DE SHERBROOKE   (Canada)

^ae ST MICHAEL'S HOSPITAL   (Canada)

^af UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^ag CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^ah MCGILL UNIVERSITY   (Canada)

^ai UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

^aj MONTREAL HEART INSTITUTE   (Canada)

^ak WESTERN UNIVERSITY   (Canada)

^al MCMASTER UNIVERSITY   (Canada)

^am Groupes de médecine de famille   (Canada)

^an SIMON FRASER UNIVERSITY   (Canada)

^ao HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^ap ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^aq UNIVERSITY OF MONTREAL   (Canada)

^ar CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ANTIHYPERTENSIVE AGENT;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BRAIN HEMORRHAGE; CANADA; CARDIOVASCULAR RISK; EVIDENCE BASED MEDICINE; FIBROMUSCULAR DYSPLASIA; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MONOTHERAPY; PRACTICE GUIDELINE; RENOVASCULAR HYPERTENSION; RISK ASSESSMENT; SYSTOLIC BLOOD PRESSURE; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; CLASSIFICATION; COMORBIDITY; DRUG EFFECTS; FEMALE; MALE; MEDICATION THERAPY MANAGEMENT; MIDDLE AGED; PROCEDURES; STANDARDS;

ADULT; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; CANADA; COMORBIDITY; DIURETICS; FEMALE; HUMANS; HYPERTENSION; MALE; MEDICATION THERAPY MANAGEMENT; MIDDLE AGED; RISK ASSESSMENT;

EID: 85018679773     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2017.09.006     Document Type: Erratum

References (88)

1. 1 Padwal, R.S., Bienek, A., McAlister, F.A., Campbell, N.R., Outcomes Research Task Force of the Canadian Hypertension Education Program. Epidemiology of hypertension in Canada: an update. Can J Cardiol 32 (2016), 687–694.
2. 2 Kannel, W.B., Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 275 (1996), 1571–1576.
3. 3 Yusuf, S., Hawkins, S., Ounpuu, S., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364 (2004), 937–952.
4. 4 Lim, S.S., Vos, T., Flaxman, A.D., et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380 (2012), 2224–2260.
5. 5 Chow, C.K., Teo, K.K., Rangarajan, S., et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA 310 (2013), 959–968.
6. 6 Feldman, R.D., Campbell, N., Larochelle, P., et al. 1999 Canadian recommendations for the management of hypertension. Task Force for the Development of the 1999 Canadian Recommendations for the Management of Hypertension. CMAJ 161:suppl 12 (1999), S1–S17.
7. 7 McAlister, F.A., Wilkins, K., Joffres, M., et al. Changes in the rates of awareness, treatment and control of hypertension in Canada over the past two decades. CMAJ 183 (2011), 1007–1013.
8. 8 Zarnke, K.B., Levine, M., McAlister, F.A., et al. The 2000 Canadian recommendations for the management of hypertension: part two–diagnosis and assessment of people with high blood pressure. Can J Cardiol 17 (2001), 1249–1263.
9. 9 Zarnke, K.B., McAlister, F.A., Campbell, N.R., et al. The 2001 Canadian recommendations for the management of hypertension: part one–assessment for diagnosis, cardiovascular risk, causes and lifestyle modification. Can J Cardiol 18 (2002), 604–624.
10. 10 McAlister, F.A., Zarnke, K.B., Campbell, N.R., et al. The 2001 Canadian recommendations for the management of hypertension: part two–therapy. Can J Cardiol 18 (2002), 625–641.
11. 11 Canadian Hypertension Education Program. The Canadian recommendations for the management of hypertension. Can Pharm J 136 (2003), 45–52.
12. 12 Hemmelgarn, B.R., Zarnke, K.B., Campbell, N.R., et al. The 2004 Canadian Hypertension Education Program recommendations for the management of hypertension: part i–blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol 20 (2004), 31–40.
13. 13 Khan, N.A., McAlister, F.A., Campbell, N.R., et al. The 2004 Canadian recommendations for the management of hypertension: part II–therapy. Can J Cardiol 20 (2004), 41–54.
14. 14 Touyz, R.M., Campbell, N., Logan, A., et al. The 2004 Canadian recommendations for the management of hypertension: part III–lifestyle modifications to prevent and control hypertension. Can J Cardiol 20 (2004), 55–59.
15. 15 Hemmelgarn, B.R., McAllister, F.A., Myers, M.G., et al. The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part 1- blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol 21 (2005), 645–656.
16. 16 Khan, N.A., McAlister, F.A., Lewanczuk, R.Z., et al. The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part II - therapy. Can J Cardiol 21 (2005), 657–672.
17. 17 Hemmelgarn, B.R., McAlister, F.A., Grover, S., et al. The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: part I–blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol 22 (2006), 573–581.
18. 18 Khan, N.A., McAlister, F.A., Rabkin, S.W., et al. The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: part II - therapy. Can J Cardiol 22 (2006), 583–593.
19. 19 Padwal, R.S., Hemmelgarn, B.R., McAlister, F.A., et al. The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 1- blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol 23 (2007), 529–538.
20. 20 Khan, N.A., Hemmelgarn, B., Padwal, R., et al. The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2-therapy. Can J Cardiol 23 (2007), 539–550.
21. 21 Padwal, R.S., Hemmelgarn, B.R., Khan, N.A., et al. The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: part 1-blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol 24 (2008), 455–463.
22. 22 Khan, N.A., Hemmelgarn, B., Herman, R.J., et al. The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2-therapy. Can J Cardiol 24 (2008), 465–475.
23. 23 Padwal, R.S., Hemmelgarn, B.R., Khan, N.A., et al. The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: part 1–blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol 25 (2009), 279–286.
24. 24 Khan, N.A., Hemmelgarn, B., Herman, R.J., et al. The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2–therapy. Can J Cardiol 25 (2009), 287–298.
25. 25 Quinn, R.R., Hemmelgarn, B.R., Padwal, R.S., et al. The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part I - blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol 26 (2010), 241–248.
26. 26 Hackam, D.G., Khan, N.A., Hemmelgarn, B.R., et al. The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2-therapy. Can J Cardiol 26 (2010), 249–258.
27. 27 Rabi, D.M., Daskalopoulou, S.S., Padwal, R.S., et al. The 2011 Canadian Hypertension Education Program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. Can J Cardiol 27 (2011), 415–433.
28. 28 Daskalopoulou, S.S., Khan, N.A., Quinn, R.R., et al. The 2012 Canadian Hypertension Education Program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. Can J Cardiol 28 (2012), 270–287.
29. 29 Hackam, D.G., Quinn, R.R., Ravani, P., et al. The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol 29 (2013), 528–542.
30. 30 Dasgupta, K., Quinn, R.R., Zarnke, K.B., et al. The 2014 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol 30 (2014), 485–501.
31. 31 Daskalopoulou, S.S., Rabi, D.M., Zarnke, K.B., et al. The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol 31 (2015), 549–568.
32. 32 Leung, A.A., Nerenberg, K., Daskalopoulou, S.S., et al. Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol 32 (2016), 569–588.
33. 33 McAlister, F.A., The Canadian Hypertension Education Program–a unique Canadian initiative. Can J Cardiol 22 (2006), 559–564.
34. 34 Brouwers, M.C., Kho, M.E., Browman, G.P., et al. AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ 182 (2010), E839–E842.
35. 35 Andreoni, K.A., Weeks, S.M., Gerber, D.A., et al. Incidence of donor renal fibromuscular dysplasia: does it justify routine angiography?. Transplantation 73 (2002), 1112–1116.
36. 36 Blondin, D., Lanzman, R., Schellhammer, F., et al. Fibromuscular dysplasia in living renal donors: still a challenge to computed tomographic angiography. Eur J Radiol 75 (2010), 67–71.
37. 37 Cragg, A.H., Smith, T.P., Thompson, B.H., et al. Incidental fibromuscular dysplasia in potential renal donors: long-term clinical follow-up. Radiology 172 (1989), 145–147.
38. 38 Neymark, E., LaBerge, J.M., Hirose, R., et al. Arteriographic detection of renovascular disease in potential renal donors: incidence and effect on donor surgery. Radiology 214 (2000), 755–760.
39. 39 Plouin, P.F., Perdu, J., La Batide-Alanore, A., et al. Fibromuscular dysplasia. Orphanet J Rare Dis, 2, 2007, 28.
40. 40 Spring, D.B., Salvatierra, O. Jr., Palubinskas, A.J., et al. Results and significance of angiography in potential kidney donors. Radiology 133 (1979), 45–47.
41. 41 Slovut, D.P., Olin, J.W., Fibromuscular dysplasia. N Engl J Med 350 (2004), 1862–1871.
42. 42 Olin, J.W., Froehlich, J., Gu, X., et al. The United States Registry for Fibromuscular Dysplasia: results in the first 447 patients. Circulation 125 (2012), 3182–3190.
43. 43 Mettinger, K.L., Fibromuscular dysplasia and the brain. II. Current concept of the disease. Stroke 13 (1982), 53–58.
44. 44 Olin, J.W., Gornik, H.L., Bacharach, J.M., et al. Fibromuscular dysplasia: state of the science and critical unanswered questions: a scientific statement from the American Heart Association. Circulation 129 (2014), 1048–1078.
45. 45 Olin, J.W., Piedmonte, M.R., Young, J.R., et al. The utility of duplex ultrasound scanning of the renal arteries for diagnosing significant renal artery stenosis. Ann Intern Med 122 (1995), 833–838.
46. 46 Riehl, J., Schmitt, H., Bongartz, D., Bergmann, D., Sieberth, H.G., Renal artery stenosis: evaluation with colour duplex ultrasonography. Nephrol Dial Transplant 12 (1997), 1608–1614.
47. 47 Textor, S.C., Pitfalls in imaging for renal artery stenosis. Ann Intern Med 141 (2004), 730–731.
48. 48 Vasbinder, G.B., Nelemans, P.J., Kessels, A.G., et al. Accuracy of computed tomographic angiography and magnetic resonance angiography for diagnosing renal artery stenosis. Ann Intern Med 141 (2004), 674–682 [discussion: 682].
49. 49 Sacks, F., Svetkey, L., Vollmer, W., et al. Effects on blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (DASH) diet. N Engl J Med 344 (2001), 3–10.
50. 50 Moore, T.J., Vollmer, W.M., Appel, L.J., et al. Effect of dietary patterns on ambulatory blood pressure: results from the Dietary Approaches to Stop Hypertension (DASH) trial. DASH Collaborative Research Group. Hypertension 34 (1999), 472–477.
51. 51 Karanja, N.M., Obarzanek, E., Lin, P.H., et al. Descriptive characteristics of the dietary patterns used in the Dietary Approaches to Stop Hypertension trial. DASH Collaborative Research Group. J Am Diet Assoc 99 (1999), S19–S27.
52. 52 Appel, L., Moore, T., Obarzanek, E., et al. A clinical trial of the effects of dietary patterns on blood pressure. N Engl J Med 336 (1997), 1117–1124.
53. 53 Warwick, J., Falaschetti, E., Rockwood, K., et al. No evidence that frailty modifies the positive impact of antihypertensive treatment in very elderly people: an investigation of the impact of frailty upon treatment effect in the HYpertension in the Very Elderly Trial (HYVET) study, a double-blind, placebo-controlled study of antihypertensives in people with hypertension aged 80 and over. BMC Med, 13, 2015, 78.
54. 54 Williamson, J.D., Supiano, M.A., Applegate, W.B., et al. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged >/=75 years: a randomized clinical trial. JAMA 315 (2016), 2673–2682.
55. 55 Wright, J.T. Jr., Williamson, J.D., Whelton, P.K., et al. A randomized trial of intensive versus standard blood pressure control. N Engl J Med 373 (2015), 2103–2116.
56. 56 Xie, X., Atkins, E., Lv, J., et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet 387 (2016), 435–443.
57. 57 Olde Engberink, R.H., Frenkel, W.J., van den Bogaard, B., et al. Effects of thiazide-type and thiazide-like diuretics on cardiovascular events and mortality: systematic review and meta-analysis. Hypertension 65 (2015), 1033–1040.
58. 58 Roush, G.C., Ernst, M.E., Kostis, J.B., Tandon, S., Sica, D.A., Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone: antihypertensive and metabolic effects. Hypertension 65 (2015), 1041–1046.
59. 59 Pareek, A.K., Messerli, F.H., Chandurkar, N.B., et al. Efficacy of low-dose chlorthalidone and hydrochlorothiazide as assessed by 24-h ambulatory blood pressure monitoring. J Am Coll Cardiol 67 (2016), 379–389.
60. 60 Corrao, G., Nicotra, F., Parodi, A., et al. Cardiovascular protection by initial and subsequent combination of antihypertensive drugs in daily life practice. Hypertension 58 (2011), 566–572.
61. 61 Gradman, A.H., Parise, H., Lefebvre, P., et al. Initial combination therapy reduces the risk of cardiovascular events in hypertensive patients: a matched cohort study. Hypertension 61 (2013), 309–318.
62. 62 Feldman, R.D., Zou, G.Y., Vandervoort, M.K., et al. A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial. Hypertension 53 (2009), 646–653.
63. 63 Jamerson, K., Weber, M.A., Bakris, G.L., et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 359 (2008), 2417–2428.
64. 64 Lonn, E.M., Bosch, J., Lopez-Jaramillo, P., et al. Blood-pressure lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med 374 (2016), 2009–2020.
65. 65 Sherrill, B., Halpern, M., Khan, S., Zhang, J., Panjabi, S., Single-pill vs free-equivalent combination therapies for hypertension: a meta-analysis of health care costs and adherence. J Clin Hypertens (Greenwich) 13 (2011), 898–909.
66. 66 Taylor, A.A., Shoheiber, O., Adherence to antihypertensive therapy with fixed-dose amlodipine besylate/benazepril HCl versus comparable component-based therapy. Congest Heart Fail 9 (2003), 324–332.
67. 67 Law, M.R., Wald, N.J., Morris, J.K., Jordan, R.E., Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ, 326, 2003, 1427.
68. 68 Wald, D.S., Law, M., Morris, J.K., Bestwick, J.P., Wald, N.J., Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 122 (2009), 290–300.
69. 69 Cushman, W.C., Ford, C.E., Cutler, J.A., et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) 4 (2002), 393–404.
70. 70 ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT) [errata in: 2004;291:2196, 2003;289:178]. JAMA 288 (2002), 2981–2997.
71. 71 Hansson, L., Zanchetti, A., Carruthers, S.G., et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351 (1998), 1755–1762.
72. 72 Julius, S., Kjeldsen, S.E., Weber, M., et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363 (2004), 2022–2031.
73. 73 Dahlof, B., Sever, P.S., Poulter, N.R., et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366 (2005), 895–906.
74. 74 D'Agostino, R.B. Sr, Vasan, R.S., Pencina, M.J., et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 117 (2008), 743–753.
75. 75 Bangalore, S., Messerli, F.H., Wun, C.C., et al. J-curve revisited: an analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. Eur Heart J 31 (2010), 2897–2908.
76. 76 Bangalore, S., Qin, J., Sloan, S., Murphy, S.A., Cannon, C.P., What is the optimal blood pressure in patients after acute coronary syndromes?: Relationship of blood pressure and cardiovascular events in the PRavastatin OR atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction (PROVE IT-TIMI) 22 trial. Circulation 122 (2010), 2142–2151.
77. 77 Messerli, F.H., Mancia, G., Conti, C.R., et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous?. Ann Intern Med 144 (2006), 884–893.
78. 78 Rabkin, S.W., Shiekh, I.A., Wood, D.A., The impact of left ventricular mass on diastolic blood pressure targets for patients with coronary artery disease. Am J Hypertens 29 (2016), 1085–1093.
79. 79 Rabkin, S.W., Considerations in understanding the coronary blood flow- left ventricular mass relationship in patients with hypertension. Curr Cardiol Rev 13 (2017), 75–83.
80. 80 Anderson, C.S., Heeley, E., Huang, Y., et al. Rapid blood pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med 368 (2013), 2355–2365.
81. 81 Qureshi, A.I., Palesch, Y.Y., Barsan, W.G., et al. Intensive blood pressure lowering in patients with acute cerebral hemorrhage. N Engl J Med 375 (2016), 1033–1043.
82. 82 Davies, M.G., Saad, W.E., Peden, E.K., et al. The long-term outcomes of percutaneous therapy for renal artery fibromuscular dysplasia. J Vasc Surg 48 (2008), 865–871.
83. 83 Trinquart, L., Mounier-Vehier, C., Sapoval, M., Gagnon, N., Plouin, P.F., Efficacy of revascularization for renal artery stenosis caused by fibromuscular dysplasia: a systematic review and meta-analysis. Hypertension 56 (2010), 525–532.
84. 84 Calhoun, D.A., Jones, D., Textor, S., et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 117 (2008), e510–e526.
85. 85 de la Sierra, A., Segura, J., Banegas, J.R., et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 57 (2011), 898–902.
86. 86 Roberie, D.R., Elliott, W.J., What is the prevalence of resistant hypertension in the United States?. Curr Opin Cardiol 27 (2012), 386–391.
87. 87 Sim, J.J., Bhandari, S.K., Shi, J., et al. Characteristics of resistant hypertension in a large, ethnically diverse hypertension population of an integrated health system. Mayo Clin Proc 88 (2013), 1099–1107.
88. 88 Williams, B., MacDonald, T.M., Morant, S., et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 386 (2015), 2059–2068.